Business
New Rapid Molecular Test For Tuberculosis Can Simultaneously Detect Resistance To First- And Second-Line Drugs
New Rapid Molecular Test For Tuberculosis Can Simultaneously Detect Resistance To First- A...
About this update from Discovery Harbour Resources Corp.
[{"type":"text","content":"\n\n\n\nNew Rapid Molecular Test For Tuberculosis Can Simultaneously Detect Resistance To First- And Second-Line Drugs\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nGENEVA and SUNNYVALE, Calif., July 16, 2020\n\n\n\nXpert® MTB/XDR cartridge enables expanded drug-resistance profiling in less than 90 minutes Used to empower clinicians to quickly prescribe treatment regimens for multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), the test could help fill a critical gap that is currently jeopardizing global TB targets GENEVA and SUNNYVALE, Calif., July 16, 2020 /CNW/ -- The Foundation for Innovative New Diagnostics (FIND) and Cepheid, Inc, announced today the launch of the new Xpert® MTB/XDR* test, which enables expanded drug-resistance tuberculosis (TB) profiling in less than 90 minutes. Xpert MTB/XDR can be used to empower clinicians to quickly prescribe treatment regimens for extensively drug-resistant TB (XDR-TB). \n\n \n \n \n \n \n \n\n \nAble to detect TB that is resistant to multiple first- and second-line TB drugs, the test could help fill a critical gap that is currently jeopardizing global TB elimination targets. By contrast, current methods for identifying drug-resistance profiles for XDR-TB are very complex to perform, can take up to 16 weeks to deliver results, and as a result are often completely unavailable to patients.1 \nXDR-TB is the most complicated form of TB, with the worst outcomes. Mortality has been reported as high as 41% in some cohorts.2 The scientific community has been focused on coordinating innovation to improve both diagnosis and treatment of XDR-TB for years.3,4 The World Health Organization (WHO) recommends rapid molecular testing and detection of drug-resistant TB as an essential condition for the implementation of new treatment regimens.5\n\"An ordinary TB diagnosis is awful, but XDR-TB is the worst nightmare of every TB doctor and every patient,\" said Catharina Boehme, CEO of FIND. \"Recent treatment advances are already making a huge impact, but for the best chances of su...